CSL Ltd. is a leading pharmaceutical company based in Australia with a Risk Rating Score of 24.4, categorizing it as a Medium Risk company. Known for its focus on environment, sustainability, and governance (ESG), CSL has two key segments - CSL Behring and Seqirus. CSL Behring offers treatments for various conditions using plasma-derived proteins or recombinants, while Seqirus is a major player in the influenza vaccination market. With a strong R&D track record, CSL is expanding its product portfolio with a focus on nonplasma products. Originally founded in Australia, CSL now generates a significant portion of its revenue from North America and Europe.